Amicus Therapeutics, Inc. (NASDAQ:FOLD) major shareholder Perceptive Advisors Llc bought 20,000 shares of Amicus Therapeutics stock in a transaction on Monday, September 24th. The shares were bought at an average price of $12.45 per share, for a total transaction of $249,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of FOLD opened at $13.44 on Monday. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30. Amicus Therapeutics, Inc. has a 1 year low of $11.57 and a 1 year high of $17.62. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -4.60 and a beta of 1.33.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.33). Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. The firm had revenue of $21.31 million for the quarter, compared to analysts’ expectations of $18.92 million. As a group, equities analysts predict that Amicus Therapeutics, Inc. will post -1.19 earnings per share for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Exane Derivatives bought a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $137,000. Arbor Wealth Management LLC bought a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $144,000. P.R. Herzig & Co. Inc. bought a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $156,000. Quantitative Systematic Strategies LLC bought a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $179,000. Finally, TCW Group Inc. bought a new position in shares of Amicus Therapeutics during the 2nd quarter valued at about $245,000.
A number of equities analysts have issued reports on FOLD shares. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a report on Tuesday, July 10th. ValuEngine cut Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 19th. BidaskClub cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 28th. Finally, Chardan Capital cut Amicus Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $15.00 in a report on Friday, August 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $19.80.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Featured Story: Analyst Ratings
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.